Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan
- PMID: 19171699
- DOI: 10.1200/JCO.2008.20.8769
Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan
Comment on
-
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.J Clin Oncol. 2008 Nov 10;26(32):5147-50. doi: 10.1200/JCO.2008.18.5447. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854559 Free PMC article. No abstract available.
-
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
